<DOC>
	<DOC>NCT02486510</DOC>
	<brief_summary>Effect on HIV-1 cell reservoirs of the concomitant administration of intensive chemotherapy and the pharmacological blockade of CCR5 coreceptors: a pilot, open, randomized, and controlled clinical trial.</brief_summary>
	<brief_title>Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients who give written consent to participate in the study Age between 18 and 65 years old, included. Chronic HIV1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by genotyping in plasma samples stored Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma With or without stable antiretroviral therapy Patients that are able to understand the purpose of the study and be available for scheduled appointments. Both in the case of female and male patients, the patient agrees to use a double barrier method of contraception from the moment of signing the informed consent until 3 months after the end of their participation in the study. To have planned antiretroviral treatment interruption during the participation in the study Hypersensitivity to products used in this study To be involved in another clinical trial or received an investigational drug within 3 months prior to the study initiation To have contraindications or limitations to perform leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CCR5 coreceptors</keyword>
	<keyword>Maraviroc</keyword>
</DOC>